Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Mutations in the p53 tumor suppressor are the most frequently observed genetic alterations in human cancer. The majority of the mutations occur in the core domain which contains the sequence-specific DNA binding activity of the p53 protein (residues 102-292), and they result in loss of DNA binding. The crystal structure of a complex containing the core domain of human p53 and a DNA binding site has been determined at 2.2 angstroms resolution and refined to a crystallographic R factor of 20.5 percent. The core domain structure consists of a beta sandwich that serves as a scaffold for two large loops and a loop-sheet-helix motif. The two loops, which are held together in part by a tetrahedrally coordinated zinc atom, and the loop-sheet-helix motif form the DNA binding surface of p53. Residues from the loop-sheet-helix motif interact in the major groove of the DNA, while an arginine from one of the two large loops interacts in the minor groove. The loops and the loop-sheet-helix motif consist of the conserved regions of the core domain and contain the majority of the p53 mutations identified in tumors. The structure supports the hypothesis that DNA binding is critical for the biological activity of p53, and provides a framework for understanding how mutations inactivate it.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Modification of any of five arginine residues that are hotspots for TP53 mutations in human cancers disables TP53 sequence-specific DNA binding (Cho, et al., 1994).”
From The Mdm network and its regulation of p53 activities: a rheostat of cancer risk (2014) · cites this paper as Cho, et al., 1994
In the citing paper
“Gly-245 in the wild type adopts unusual backbone dihedral angles (1), which are not favored when the residue is replaced by serine.”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“The crystal structure of p53 core domain shows that the epitope of PAb240, located in strand 7, is inaccessible to antibody binding (1), and at least a partly unfolded form is required to expose the epitope.”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“The guanidinium group of Arg-249 is salt-bridged to the carboxylate group of Glu-171 in L2 and backbone oxygens of Gly-245 and Met-246 (1).”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“suggesting the structure of p53 core domain in solution is similar to that in crystal structure (1).”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kabsch, W., & Sander, C. (1983) · Biopolymers · doi:10.1002/bip.360221211 · Cited by 15,320
Jones, T. A., Zou, J. Y., Cowan, S. W., & Kjeldgaard, M. (1991) · Acta Crystallographica Section A Foundations of Crystallography · doi:10.1107/s0108767390010224 · Cited by 12,648
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Principles of Nucleic Acid Structure
Saenger, W. (1984) · Springer Advanced Texts in Chemistry · doi:10.1007/978-1-4612-5190-3 · Cited by 4,150
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
Research works printed but not linked: 2
- SACK, J. S., JOURNAL OF MOLECULAR GRAPHICS 6: 224 (1988).
- TONRUD, D.E., ACTA CRYSTALLOGR A 43: 489 (1987).
Cited by
Items 1,001–1,100 of 2,517
Molecular mimicry of the NF-κB DNA target site by a selected RNA aptamer
Ghosh, G., Huang, D.-B., & Huxford, T. (2004) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2004.01.004 · Cited by 40
p53 gene mutations in rectal cancer associated with schistosomiasis japonica in Chinese patients
Zhang, R., Takahashi, S., Orita, S.-I., et al. (1998) · Cancer Letters · doi:10.1016/s0304-3835(98)00154-2 · Cited by 41
Cai, L., & Cherian, M. G. (1996) · Mutation Research/Genetic Toxicology · doi:10.1016/s0165-1218(96)90028-2 · Cited by 41
Origins of Anti‐DNA Antibodies and Their Implications for B‐Cell Tolerancea
Radic, M. Z., & WEIGERT, M. G. (1995) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1995.tb55853.x · Cited by 43
Hypomethylation of pericentromeric DNA in breast adenocarcinomas
Narayan, A., Ji, W., Zhang, X.-Y., Marrogi, A., Graff, J. R., Baylin, S. B., & Ehrlich, M. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980911)77:6<833::aid-ijc6>3.0.co;2-v · Cited by 266
Kinetic Partitioning During Folding of the p53 DNA Binding Domain
Butler, J. S., & Loh, S. N. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.05.060 · Cited by 41
Borah, S., Verma, S. C., & Robertson, E. S. (2004) · Journal of Virology · doi:10.1128/jvi.78.19.10336-10347.2004 · Cited by 41
“The crystal structures of the DNA-binding domain and the tetramerization domain have been solved and demonstrate that these domains are capable of retaining structure and function when expressed independently of other portions of the protein (11, 34).”
BackgroundHoehner, J., Gestblom, C., Olsen, L., & Påhlman, S. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.203 · Cited by 41
Jett, S. D., Cherny, D. I., Subramaniam, V., & Jovin, T. M. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.3759 · Cited by 41
The Δ133p53 Isoforms, Tuners of the p53 Pathway
Joruiz, S. M., Beck, J. A., Horikawa, I., & Harris, C. C. (2020) · Cancers · doi:10.3390/cancers12113422 · Cited by 49
“These four conserved regions coordinate Zn2+ loops structures which are essential for p53 conformation [16,17].”
BackgroundFiore, R. D., Marcatti, M., Drago‐Ferrante, R., D’Anneo, A., Giuliano, M., Carlisi, D., Blasio, A. D., Querques, F., Pastore, L., Tesoriere, G., et al. (2014) · Bone · doi:10.1016/j.bone.2013.12.021 · Cited by 46
“cancer [48].”
Functional Census of Mutation Sequence Spaces: The Example of p53 Cancer Rescue Mutants
Danziger, S. A., Swamidass, S. J., Zeng, J., Dearth, L. R., Lü, Q., Chen, J. H., Cheng, J., Hoang, V. P., Saigo, H., Luo, R., et al. (2006) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2006.22 · Cited by 41
“All simulations were performed in the AMBER package [39] using the wild-type p53 core domain crystal structure [20] as a template.”
BackgroundMethodMutant p53 upregulates alpha-1 antitrypsin expression and promotes invasion in lung cancer
Shakya, R., Tarulli, G. A., Sheng, L., Lokman, N. A., Ricciardelli, C., Pishas, K. I., Selinger, C. I., Kohonen‐Corish, M. R. J., Cooper, W. A., Turner, A. G., et al. (2017) · Oncogene · doi:10.1038/onc.2017.66 · Cited by 43
Tanaka, T., Watanabe, M., & Yamashita, K. (2018) · Oncotarget · doi:10.18632/oncotarget.24611 · Cited by 50
“Therefore, mutation of the DNA binding region of p53 protein was considered to lead to a dysfunction in the transactivation of normal p53 protein [9].”
BackgroundThe role of TP53 gain-of-function mutation in multifocal glioblastoma
Olafson, L. R., Gunawardena, M. P., Nixdorf, S., McDonald, K. L., & Rapkins, R. W. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03318-5 · Cited by 42
Classification of Protein-DNA Complexes Based on Structural Descriptors
Prabakaran, P., Siebers, J. G., Ahmad, S., Gromiha, M. M., Singarayan, M. G., & Sarai, A. (2006) · Structure · doi:10.1016/j.str.2006.06.018 · Cited by 43
p53 Germline mutation in a patient with Li-Fraumeni Syndrome and three metachronous malignancies
Pötzsch, C., Voigtländer, T., & Lübbert, M. (2002) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-002-0360-3 · Cited by 40
“Mutations at codon 175 do not affect residues that directly contact DNA but residues that stabilize the DNA structure by connecting two of the loops (Cho et al. 1994).”
BackgroundMutations in Zinc‐binding Domains of p53 as a Prognostic Marker of Esophageal‐cancer Patients
Kihara, C., Seki, T., Furukawa, Y., Yamana, H., Kimura, Y., van Schaardenburgh, P., Hirata, K., & Nakamura, Y. (2000) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2000.tb00931.x · Cited by 40
Allosteric drugs: thinking outside the active-site box
DeDecker, B. S. (2000) · Chemistry & Biology · doi:10.1016/s1074-5521(00)00115-0 · Cited by 40
Refolding and structural characterization of the human p53 tumor suppressor protein
Bell, S. J., Hansen, S., & Büchner, J. (2002) · Biophysical Chemistry · doi:10.1016/s0301-4622(02)00011-x · Cited by 47
Simple identification of dominant p53 mutants by a yeast functional assay
Inga, A. (1997) · Carcinogenesis · doi:10.1093/carcin/18.10.2019 · Cited by 40
Kerbauy, F. R., Colleoni, G. W. B., Saad, S. T., et al. (2004) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190410001713170 · Cited by 40
“They are frequent in the DNA binding regions of the loops L2 and L3 and in the helix 2, where they either abrogate DNA binding or cause a decrease in the affinity between p53 and its target DNA sequence [8,9].”
BackgroundEnergetic Contribution of Residues in the Runx1 Runt Domain to DNA Binding
Li, Z., Yan, J., Matheny, C., Corpora, T., Bravo, J., Warren, A. J., Bushweller, J. H., & Speck, N. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303973200 · Cited by 41
P53, apoptosis, and breast cancer
Barnes, D. M., & Camplejohn, R. S. (1996) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/bf02013640 · Cited by 40
p53 mutations in bladder cancer: evidence for exogenous versus endogenous risk factors.
Schroeder, J. C., Conway, K., Yu, L., Mistry, K., Bell, D. A., & Taylor, J. A. (2003) · PubMed · Cited by 46
Genetic alterations in head and neck squamous cell carcinomas
Nagai, M. A. (1999) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x1999000700015 · Cited by 40
“This highly conserved region encompasses amino acids 102 to 292 containing the DNA-binding domain of the protein (50).”
BackgroundGorgoulis, V. G., Zacharatos, P., Kotsinas, A., Mariatos, G., Liloglou, T., Vogiatzi, T., Foukas, P., Rassidakis, G., Garinis, G., Ioannides, T., et al. (2000) · Molecular Medicine · doi:10.1007/bf03402115 · Cited by 40
“(97)], in fibroblasts from Li-Fraumeni syndrome patients, exhibited a dominant gain of function activity that generated chromosomal instability; whereas mutations in the specific DNA binding domain [class I mutants (97)] and truncations displayed a normal spindle checkpoint response in which cells accumulated with dip…”
BackgroundPrognostic impact of p21/waf1/cip1 in colorectal cancer
Zirbes, T. K., Baldus, S. E., Moenig, S. P., Nolden, S., Kunze, D., Shafizadeh, S. T., Schneider, P. M., Thiele, J., Hoelscher, A. H., & Dienes, H. P. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000120)89:1<14::aid-ijc3>3.0.co;2-l · Cited by 98
Clubb, R. T., Omichinski, J. G., Gronenborn, A. M., Marius Clore, G., Sakaguchi, K., & Appella, E. (1995) · Protein Science · doi:10.1002/pro.5560040505 · Cited by 37
“This structure in conjunction with the recently determined co-crystal structure of the central domain of p53 bound to DNA (Cho et al., 1994) has provided a structural framework with which to interpret the significance of tumor-derived mutants of p53.”
BackgroundExploiting the p53 Pathway for the Diagnosis and Therapy of Human Cancer
Lane, D. P. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.049 · Cited by 48
Control of p53 nuclear accumulation in stressed cells
Inoue, T. M., Wu, L., Stuart, J., & Maki, C. G. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.08.006 · Cited by 44
“In its active form, p53 is a tetramer that binds DNA and activates gene transcription [4].”
BackgroundFunctional mapping of the MH1 DNA-binding domain of DPC4/SMAD4
Jones, J. B. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.12.2363 · Cited by 39
Bista, M., Freund, S. M., & Fersht, A. R. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1214176109 · Cited by 39
“The p53 core domain as defined in the seminal work by Pavletich and coworkers is a globular β-barrel domain formed by residues 94–293 (24).”
BackgroundDemir, Ö., Baronio, R., Salehi, F., Wassman, C. D., Hall, L., Hatfield, G. W., Chamberlin, R., Kaiser, P., Lathrop, R. H., & Amaro, R. E. (2011) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002238 · Cited by 39
“These mutations may cause partial or global protein destabilization, loss of zinc coordination, or disruption of DNA contacts, and thus inactivate the tumor suppressor function of p53 (www-p53.iarc.fr) [4].”
BackgroundTichý, A., Vávrová, J., Pejchal, J., & Řezáčová, M. (2010) · Acta Medica (Hradec Kralove Czech Republic) · doi:10.14712/18059694.2016.57 · Cited by 52
“transactivation (1–67), proline (67–98), central (98–303), nuclear localization signal-containing region (303–323), oligomerization (323–363) and C-terminal domain (363–393); the central domain is responsible for binding to specific DNA sequences in the vicinity of promoter region of p53inducible genes (11).”
BackgroundBeebeejaun, Y., Athithan, A., Copeland, T. P., Kamath, M. S., Sarris, I., & Sunkara, S. K. (2021) · Fertility and Sterility · doi:10.1016/j.fertnstert.2021.01.044 · Cited by 48
P53-responsive genes and the potential for cancer diagnostics and therapeutics development
Xu, H. Y., & El-Gewely, M. R. (2001) · Biotechnology annual review · doi:10.1016/s1387-2656(01)07035-1 · Cited by 42
Restoration of Wild‐Type p53 Function in Human Tumors: Strategies for Efficient Cancer Therapy
Wiman, K. G. (2007) · Advances in cancer research · doi:10.1016/s0065-230x(06)97014-6 · Cited by 40
Dreyfus, D. H., Nagasawa, M., Gelfand, E. W., & Ghoda, L. Y. (2005) · BMC Immunology · doi:10.1186/1471-2172-6-12 · Cited by 40
“Point mutations in p53 identified in malignant cells are clustered around volutionarily conserved regions in the DNA binding region of p53 and simultaneously eliminate both sequence-specific DNA binding and transcriptional activity [12-14].”
BackgroundBensaad, K., Le Bras, M., Unsal, K., Strano, S., Blandino, G., Tominaga, O., Rouillard, D., & Soussi, T. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m208233200 · Cited by 34
VARIOUS FORMS OF MUTANT p53 CONFER SENSITIVITY TO CISPLATIN AND DOXORUBICIN IN BLADDER CANCER CELLS
Chang, F.-L., & Lai, M. (2001) · The Journal of Urology · doi:10.1016/s0022-5347(05)66150-2 · Cited by 45
The Tumor Suppressor Gene TP53: Implications for Cancer Management and Therapy
Seemann, S., Maurici, D., Olivier, M., de Fromentel, C. C., & Hainaut, P. L. (2004) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360490504952 · Cited by 44
Perez, R. E., Knights, C. D., Sahu, G., Catania, J., Kolukula, V. K., Stoler, D. L., Graessmann, A., Ogryzko, V. V., Pishvaian, M. J., Albanese, C., et al. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22285 · Cited by 43
“The high-resolution crystal structure of several p53 oncogenic mutants has shown that C-terminal residues beyond JOURNAL OF CELLULAR PHYSIOLOGY K291 are highly disordered (Cho et al., 1994; Wong et al., 1999; Joerger et al., 2006; Joerger and Fersht, 2008).”
BackgroundStructural Characterization of the Intrinsically Disordered Protein p53 Using Raman Spectroscopy
Signorelli, S., Cannistraro, S., & Bizzarri, A. R. (2016) · Applied Spectroscopy · doi:10.1177/0003702816651891 · Cited by 36
“A DNA core domain (DBD, residues 94–293) has been found to have a relatively stable structure composed by an immunoglobulin-like central b-sandwich of two antiparallel b-sheets, which provides the basic scaffold for the DNA-binding surface.(16,17) The presence of the large unstructured regions allows p53 to act as a c…”
BackgroundResultEffect ofmts1 (S100A4) expression on the progression of human breast cancer cells
Grigorian, M., Ambartsumian, N. S., Lykkesfeldt, A. E., Bastholm, L., Elling, F., Georgiev, G. P., & Lukanidin, E. M. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960917)67:6<816::aid-ijc10>3.0.co;2-# · Cited by 108
Function and Sequence Analyses of Tumor Suppressor Gene p53 of CHO.K1 Cells
Tzang, B., Lai, Y., Hsu, M., Chang, H., Chang, C., Huang, P. C., & Liu, Y.-C. (1999) · DNA and Cell Biology · doi:10.1089/104454999315376 · Cited by 42
Duan, W., Gao, L., Wu, X., Zhang, Y., Otterson, G. A., & Villalona-Calero, M. A. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2006.07.005 · Cited by 42
Cellular adaptation to hypoxia and p53 transcription regulation
Zhao, Y., Chen, X., & Du, J.-Z. (2009) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b0820293 · Cited by 42
“…activation domain that contacts TAF (TATA-binding protein and associated factors) components of TFIID (transcription factor IID), residues 1~40 (Cho et al., 1994; Thut et al., 1995); (2) a sequence-specific DNA binding domain, residues 120~290 (Cho et al., 1994; Bargonetti et al., 1993); (3) a…”
BackgroundTp53 and its potential therapeutic role as a target in bladder cancer
Ciccarese, C., Massari, F., Blanca, A., Tortora, G., Montironi, R., Cheng, L., Scarpelli, M., Raspollini, M. R., Vau, N., Fonseca, J., et al. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1297798 · Cited by 42
“Arg 175 and Arg 249) – structural mutations [56].”
BackgroundLi, L., Li, X., Tang, Y., Lao, Z., Lei, J., & Wei, G. (2020) · Physical Chemistry Chemical Physics · doi:10.1039/c9cp06671c · Cited by 40
Expression of high p53 levels in colorectal cancer: a favourable prognostic factor
Adrover, E., Maestro, M. L., Casla, M. T. S., et al. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690660 · Cited by 38
“More importantly, accumulating data indicate that not all mutant p53 proteins lose the normal p53 functions, and the function of the mutant p53 gene product is variable depending on the mutation locus (Cho et al, 1994; Levine et al, 1994).”
BackgroundPfeifer, G. P., & Holmquist, G. P. (1997) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(97)00004-8 · Cited by 45
Mutant p53 and genomic instability in a transgenic mouse model of breast cancer
Murphy, K. L., & Rosen, J. M. (2000) · Oncogene · doi:10.1038/sj.onc.1203274 · Cited by 40
Binding of p53 and its core domain to supercoiled DNA
Palecek, E., Brázdová, M., Brázda, V., Palecek, J., Billová, S., Subramaniam, V., & Jovin, T. M. (2001) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2001.01898.x · Cited by 38
Proapoptotic p53-Interacting Protein 53BP2 Is Induced by UV Irradiation but Suppressed by p53
Lopez, C. D., Ao, Y., Rohde, L. H., Perez, T. D., O’Connor, D. J., Lü, X., Ford, J. M., & Naumovski, L. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.21.8018-8025.2000 · Cited by 40
“Additionally, we cannot exclude p53-dependent transcriptional activation of other genes that could modulate 53BP2 levels because the p53 mutants examined in this report are also defective for sequence-specific DNA binding (5).”
BackgroundRoth, J. C., Koch, P., Contente, A., & Dobbelstein, M. (2000) · Oncogene · doi:10.1038/sj.onc.1203500 · Cited by 43
Choisy, C., Reisdorf, P., & Yonish-Rouach, E. (1998) · Toxicology Letters · doi:10.1016/s0378-4274(98)00238-0 · Cited by 38
Mutation of conserved domain II alters the sequence specificity of DNA binding by the p53 protein.
Freeman, J., Schmidt, S., Schärer, E., & Iggo, R. D. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06874.x · Cited by 38
Hann, B. C., & Balmain, A. (2003) · Journal of Virology · doi:10.1128/jvi.77.21.11588-11595.2003 · Cited by 42
“Several of these hotspot mutations result in disruption of the sequence-specific DNAbinding ability of p53 (4, 18).”
BackgroundEl‐Hamid, S. M. A., Sadeek, S. A., Sadek, N. B., et al. (2023) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2023.123274 · Cited by 37
Huang, X., Zhang, S., Qi, H., Wang, Z., Chen, H.-W., Shao, J., & Shen, J. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.05.026 · Cited by 44
Repurposing antiparasitic antimonials to noncovalently rescue temperature-sensitive p53 mutations
Tang, Y., Song, H., Wang, Z., Xiao, S., Xiang, X., Zhan, H., Wu, L., Wu, J., Xing, Y., Tan, Y., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110622 · Cited by 37
Fojta, M., Pivoňková, H., Brázdová, M., Němcová, K., Palecek, J. J., & Vojtěšek, B. (2004) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.2004.04323.x · Cited by 40
P53 mutations in thyroid carcinoma: Tidings from an old foe
Farid, N. R. (2001) · Journal of Endocrinological Investigation · doi:10.1007/bf03343889 · Cited by 40
An ATP/ADP-Dependent Molecular Switch Regulates the Stability of p53-DNA Complexes
Okorokov, A. L., & Milner, J. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.11.7501 · Cited by 37
Gentile, M., Jungeström, M. B., Olsen, K. E., Söderkvist, P., & Wingren, S. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00121-5 · Cited by 37
p53: functions, mutations and sarcomas
Hung, J. Y., & Anderson, R. L. (1997) · Acta Orthopaedica Scandinavica · doi:10.1080/17453674.1997.11744705 · Cited by 46
Soussi, T. (1995) · Advances in genome biology · doi:10.1016/s1067-5701(06)80005-7 · Cited by 38
Keohavong, P., Gao, W., Zheng, K., et al. (2003) · Analytical Biochemistry · doi:10.1016/j.ab.2003.09.030 · Cited by 37
Kučera, E., Speiser, P., Gnant, M., Szabo, L., Samonigg, H., Hausmaninger, H., Mittlböck, M., Fridrik, M., Seifert, M., Kubista, E., et al. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00400-6 · Cited by 37
Kubicka, S., Trautwein, C., Schrem, H., Tillmann, H. L., & Manns, M. P. (1995) · Journal of Hepatology · doi:10.1016/0168-8278(95)80199-5 · Cited by 37
Hu, J., Ma, X., Lindner, D. J., Karra, S., Hofmann, E. R., Reddy, S. P., & Kalvakolanu, D. V. (2001) · Oncogene · doi:10.1038/sj.onc.1204585 · Cited by 37
“We have shown here that the IFN/RA combination promotes p53 dependent gene expression and cell death using TR1 and Trx1. p53 has two cysteines (residues 242 and 176), which along with two histidines coordinate Zn2+ for DNA binding (Cho et al., 1994; Hainaut and Milner, 1993).”
Backgroundp53 at the crossroad between mitochondrial reactive oxygen species and necroptosis
Rius‐Pérez, S. (2023) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2023.07.022 · Cited by 40
Mahat, D. B., Kumra, H., Castro, S. A., Metcalf, E., Nguyen, K., Morisue, R., Ho, W. W., Chen, I., Sullivan, B., Yim, L. H., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.06.005 · Cited by 43
Dixit, U., Pandey, A. K., Liu, Z., Kumar, S., Neiditch, M. B., Klein, K. M., & Pandey, V. N. (2015) · Journal of Virology · doi:10.1128/jvi.00729-15 · Cited by 37
“Although Y220C mutation is 38 Å away from the conserved DNA binding domain (63), it is intriguing how this mutation could affect the DNA binding of p53.”
BackgroundMetabolic regulation of oxygen and redox homeostasis by p53: Lessons from evolutionary biology?
Zhuang, J., Ma, W., Lago, C. U., & Hwang, P. M. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.07.026 · Cited by 40
“Cysteine residues 176, 238, and 242 of p53 are known to coordinate zinc and play a critical role in its DNA binding and transactivating activities [49].”
Prognostic significance of p53 gene mutations and p53 protein expression in synovial sarcomas
Schneider‐Stock, R., Onnasch, D., Haeckel, C., et al. (1999) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s004280050418 · Cited by 36
“Therefore, mutations of codons 128 and 248 lead to the loss of DNA-binding ability that is critical for the tumour suppressing function of p53 [ 4 ].”
BackgroundDOBES, P., Podhorec, J., Coufal, O., Jurečková, A., Petráková, K., Vojtěšek, B., & Hrstka, R. (2014) · Oncology Reports · doi:10.3892/or.2014.3346 · Cited by 43
Somatic alterations of the p53 tumor suppressor gene in vaccine-associated feline sarcoma
Banerji, N., & Kanjilal, S. (2006) · American Journal of Veterinary Research · doi:10.2460/ajvr.67.10.1766 · Cited by 36
Janz, C., Süße, S., & Wiesmüller, L. (2002) · Oncogene · doi:10.1038/sj.onc.1205292 · Cited by 36
“…interactions and by stabilizing contacts with prebound Rad51 and other proteins. p53(273H) represents a DNA contact mutant devoid of an arginine, which is critical for sequence-independent DNA-binding due to its involvement in electrostatic interactions with a phosphate group (Cho et al., 1994).”
BackgroundMethodWright, J. D., Noskov, S. Y., & Lim, C. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.7.1563 · Cited by 41
“For the consensus site studied here, 7GGGCA11 12AGTCT16, DNA binding specificity stems from hydrogen bonding interactions between the side chains of K120, C277 and R280 and the base oxygen or nitrogen of Gua 8, Gua 9, Cyt 9′ and Gua 10′ in the major groove, while non-specific binding affinity is due to salt bridges be…”
BackgroundMethodInfluentialAnalysis of p53 “Latency” and “Activation” by Fluorescence Correlation Spectroscopy
Woelcke, J., Reimann, M., Klumpp, M., Göhler, T., Kim, E. L., & Deppert, W. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303615200 · Cited by 36
Structural Basis for p53 Binding-induced DNA Bending
Pan, Y., & Nussinov, R. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605908200 · Cited by 38
p53 gene status and chemosensitivity of childhood acute lymphoblastic leukemia cells to adriamycin
Lam, V., McPherson, J., Salmena, L., Lees, J., Chu, W., Sexsmith, E., Hedley, D. W., Freedman, M. H., Reed, J. C., Malkin, D. M., et al. (1999) · Leukemia Research · doi:10.1016/s0145-2126(99)00102-2 · Cited by 40
“Mutations within this domain result in an alteration of the tumor suppressive activity of p53 due to either reduced DNA binding ability of the protein or to changes in the structural conformation of this domain [28].”
BackgroundInfluentialGualberto, A., Hixon, M. L., Finco, T. S., Perkins, N. D., Nabel, G. J., & Baldwin, A. S. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.6.3450 · Cited by 37
“Several of the mutant forms of p53 exhibit mutations in amino acids that are known to critically contact residues in the p53 consensus site (13).”
BackgroundKoukouritaki, S. B., Theodoropoulos, P. A., Margioris, A. N., Gravanis, A., & Stournaras, C. (1996) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(199608)62:2<251::aid-jcb13>3.0.co;2-o · Cited by 72
Genetics of Follicular Thyroid Cancer
Farid, N. R., Zou, M., & Shi, Y. (1995) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(18)30024-0 · Cited by 40
Hansen, S., Lane, D. P., & Midgley, C. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.1507 · Cited by 41
Niu, L., Qin, H., Xi, H., Wei, B., Xia, S., & Chen, L. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000430154 · Cited by 39
p53: Its Mutations and Their Impact on Transcription
Vaughan, C. A., Pearsall, I., Yeudall, W. A., Deb, S. P., & Deb, S. (2014) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-017-9211-0_4 · Cited by 40
Ganguly, D., & Chen, J. (2015) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004247 · Cited by 39
“Aided by several crystal structures [34,35], the molecular basis for p53 inactivation of DBD cancer mutants can be understood in terms of either disrupting DNA contacts, perturbing the structure of DNA-binding interface, or affecting the DBD stability [32].”
BackgroundSchilling, T., Kairat, A., Melino, G., Krammer, P. H., Stremmel, W., Oren, M., & Müller, M. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.03.082 · Cited by 36
Crujeiras, A. B., Fernández, B. C., Carreira, M. C., Amil, M., Cueva, J. F., Andrade, S., Seoane, L. M., Pardo, M., Sueiro, A. M., Baltar, J., et al. (2015) · International Journal of Obesity · doi:10.1038/ijo.2015.208 · Cited by 36
Khan, P., Manna, A., Saha, S., Mohanty, S., Mukherjee, S., Mazumdar, M., Guha, D., & Das, T. (2016) · BMC Cancer · doi:10.1186/s12885-016-2078-7 · Cited by 35
Two p53 tetramers bind one consensus DNA response element
Kearns, S., Lurz, R., Orlova, E. V., & Okorokov, A. L. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw215 · Cited by 37
“The mechanism of DNA recognition by p53 was proposed on the basis of the crystallographic structure of the isolated p53 core domain bound to a specific DNA target (22).”
BackgroundResultGini, B., Thomas, N. J., & Blakely, C. M. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2020.03.78 · Cited by 38
“Many TP53 mutations affect the DBD and generate a mutated protein with a dominant negative effect (76).”
BackgroundCancer-related Mutations with Local or Long-range Effects on an Allosteric Loop of p53
Degn, K., Beltrame, L., Dahl Hede, F., Sora, V., Nicolaci, V., Vabistsevits, M., Schmiegelow, K., Wadt, K., Tiberti, M., Lambrughi, M., et al. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167663 · Cited by 34
Méplan, C., Verhaegh, G. W. C. T., Richard, M., & Hainaut, P. L. (1999) · Proceedings of The Nutrition Society · doi:10.1017/s0029665199000749 · Cited by 34
Kim, D.-H., Kim, E.-H., Na, H.-K., Sun, Y., & Surh, Y.-J. (2010) · Oncogene · doi:10.1038/onc.2010.8 · Cited by 36
Mechanism of initiation of aggregation of p53 revealed by Φ-value analysis
Wang, G., & Fersht, A. R. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1500243112 · Cited by 35
“Arg282, a mutational oncogenic hotspot (8), plays a structural role in packing of the helix H2 onto the S2-S2′ β-hairpin.”
Background
Metadata
- Authors
- Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Venue
- Science
- Published
- 1994-07-15
- Volume
- 265
- Issue
- 5170
- Pages
- 346-355
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2096276671
- Semantic Scholar
- 11096f3b08e172ce5e261795b6749818ee59c03d
- Cited by
- 2,551
- References
- 62
- Citations by year
- 2026: 62 · 2025: 52 · 2024: 40 · 2023: 64 · 2022: 61 · 2021: 73 · 2020: 67 · 2019: 62 · 2018: 61 · 2017: 54 · 2016: 64 · 2015: 62 · 2014: 81 · 2013: 78 · 2012: 68
- FWCI
- 64.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Open Access System for Information Sharing (Pohang University of Science and Technology) (submittedVersion)
- Funders
- National Cancer Institute (NCI CA08748-29)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Structural Biology › Enzyme Structure and Function
- Keywords
- p53 tumor suppressor, p53 core domain, DNA binding, zinc coordination, beta-sandwich, cancer genetics
- MeSH terms
- Amino Acid Sequence, Base Sequence, Binding Sites, Computer Graphics, Crystallization, DNA, Hydrogen Bonding, Models, Molecular, Molecular Sequence Data, Mutation, Nucleic Acid Conformation, Protein Conformation, Genes, p53, Tumor Suppressor Protein p53, Protein Structure, Secondary, Crystallography, X-Ray
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.